EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market is segmented By Treatment (EGFR-TKI Inhibitors, Immunotherapy), By Stages of the Disease (Early-stage NSCLC, Metastatic NSCLC), By Therapy Approvals (First-line Treatments, Second-line Treatments), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).The report offers the value (in USD billion) for the above-mentioned segments.
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Size
Market Size in USD
CAGR7.7%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 7.7% |
| Market Concentration | High |
| Major Players | AstraZeneca, Janssen Pharmaceuticals, Pfizer, Roche, Novartis |
please let us know !
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Analysis
The EGFR non-small cell lung cancer (EGFR + NSCLC) market is estimated to be valued at USD 4.31 Bn in 2024 and is expected to reach USD 7.27 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031. The increasing prevalence of lung cancer across the world and rising focus on targeted therapies to treat NSCLC are fueling the growth of this market.